Sodium oxybate for excessive daytime sleepiness in Parkinson disease: An open-label polysomnographic study

Archives of Neurology

Volumn 65, Issue 10, 2008, Pages 1337-1340

  Ondo, William G ^a   Perkins, Thomas ^c   Swick, Todd ^b   Hull Jr , Keith L ^c   Jimenez, J Ernesto ^a   Garris, Tippy S ^c   Pardi, Daniel ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Raleigh Neurology Associates   (United States)

^d JAZZ PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; OXYBATE SODIUM;

ADULT; ALERTNESS; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENURESIS; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; INSOMNIA; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NAUSEA; NIGHT SLEEP; NOCTURIA; OPEN STUDY; PARKINSON DISEASE; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SLEEP APNEA SYNDROME; SLOW WAVE SLEEP; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADJUVANTS, ANESTHESIA; ADULT; AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYSOMNOGRAPHY; SLEEP APNEA SYNDROMES; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; SODIUM OXYBATE; TREATMENT OUTCOME;

EID: 54049106525     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.10.1337     Document Type: Article

References (30)

1. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9(3):185-200.
2. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287(4):455-463.
3. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392-1396.
4. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord. 1999;14(6):922-927.
5. Rye DB. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology. 2004;63(8)(suppl 3):S2-S7.
6. Askenasy JJ, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J Neurol Neurosurg Psychiatry. 1990;53(9):749-753.
7. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988;11(6):512-519.
8. van Hilten B, Hoff JI, Middelkoop HA, et al. Sleep disruption in Parkinson's disease: assessment by continuous activity monitoring. Arch Neurol. 1994;51(9):922-928.
9. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003;61(1):40-45.
10. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998;51(2):526-529.
11. Wetter TC, Trenkwalder C, Gershanik O, Högl B. Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr. 2001;113(7-8):249-253.
12. Högl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology. 2003;28(10):1866-1870.
13. Wetter TC, Collado-Seidel V, Pollmacher T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep. 2000;23(3):361-367.
14. Ondo WG, Vuong K, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-424.
15. Diederich NJ, Vaillant M, Leischen M, et al. Sleep apnea syndrome in Parkinson's disease: a case-control study in 49 patients. Mov Disord. 2005;20(11):1413-1418.
16. Rye DB, Bliwise D, Dihenia B, Gurecki P. Daytime sleepiness in Parkinson's disease. J Sleep Res. 2000;9(1):63-69.
17. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341-346.
18. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology. 2002;58(7):1019-1024.
19. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003;18(3):287-293.
20. Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905-909.
21. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-1639.
22. U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31-35.
23. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939-946.
24. Lapierre O, Montplaisir J, Lamarre M, Bedard MA. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep. 1990;13(1):24-30.
25. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327-1334.
26. Boero JA, Duntley SP, Jennifer M. Sodium oxybate improves slow wave sleep and daytime sleepiness in narcolepsy [abstract]. Sleep. 2006;29(suppl):A229.
27. Lyons KE, Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg. 2006;104(4):502-505.
28. Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem. 1991;56(3):938-944.
29. Szabo ST, Gold MS, Goldberger BA, Blier P. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol Psychiatry. 2004;55(9):934-939.
30. Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med. 2007;8(2):181-183.